E
EnBiotix
EnBiotix is transforming and revitalizing existing antibiotic classes to combat the global rise of drug-resistant bacterial infections
About EnBiotix
EnBiotix is a biotechnology company specializing in the development of advanced synthetic biology solutions aimed at creating next-generation diagnostics and therapeutics. The company operates in the healthcare and pharmaceutical markets, serving clients that include biotech firms, pharmaceutical companies, and medical device manufacturers. EnBiotix's business model revolves around leveraging cutting-edge synthetic biology techniques to develop proprietary technologies, which are then licensed to other companies or used to create new products. Revenue is generated through licensing fees, partnerships, and direct sales of their innovative solutions. The company is led by Dr. Jim Collins, a pioneer in synthetic biology, whose patented technologies have been licensed by over 25 companies. EnBiotix is committed to pushing the boundaries of medical science to improve patient outcomes and address unmet medical needs.
Source: Dealroom company dataAt a glance
- Founded
- 2012
- Headquarters
- Cambridge, United States
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
- ALApeiron Holdings Limited
Vectura
Cystic Fibrosis Foundation- SBSanford Biosciences
- VVVectura Ventures
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about EnBiotix on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See EnBiotix on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.